

10th Biosimilars & Follow-On Biologics Congregation 2017

"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

9th–10th May 2017, Pestana Chelsea Bridge Hotel, London, UK

Book now...
Register now to secure your seats
Call +44 2036120886
or
email - info.uk@virtueinsight.com

Key Speakers Include

MOURAD REZK, Biogen,
Global Head Medical Affairs (Biosimilars)

ASHUTOSH PATHAK, Teva Pharmaceuticals (USA),
Senior Director, North America Medical Affairs - Oncology & Biosimilars

MATTHEW TURNER, Merck KgA,
Global Medical Director Biosimilars

NIRAJ CHHAYA, Boehringer Ingelheim,
Senior Risk Management Physician of Biosimilar Compounds

PETAR BAST, Allergan,
VP Business Intelligence

AMARDEEP UDESHI, Cipla BioTec (India),
Head – Commercial Strategy

OLEKSANDR KARPENKO, Olexacon,
Managing Director

MAARTEN VAN BAELEN, Medicines for Europe,
Market Access Director

STEPHEN MURBY, Alliance for Safe Biologic Medicines,
International Advisory Board Member, International Alliance of Patients' Organizations, Biosimilars Spokesperson

CECIL NICK, Parexel,
Vice President (Technical)

ALEX KUDRIN, Celltrion,
Biopharmaceutical Consultant

DUNCAN EMERTON, FirstWord,
Senior Director, Syndicated Insights & Analysis

OMAR ALI, University of Portsmouth and Member of NICE Adoption and Impact Reference Panel,
Visiting Lecturer

STEINAR MADSEN, Norwegian Medicines Agency,
Medical Director

SANDY EISEN, Frontline Pharma Consulting,
Chief Medical Officer

LOUISE ANGELL, Covance,
Lead Scientist, BioCMC, BioPharmaceutical CMC Solutions – Large Molecules

CHRISTOPHER STOTHERS, Arnold & Porter Kaye Scholer,
Partner

MOHAMED OUBIHI, Yakumed,
Managing Director

FEDERICO POLLANO, Polpharma Biologics,
Director Contract Manufacturing and Business Development

ASH RAMZAN, Woodley BioReg,
Principal Consultant

JOANNA BROUGHER, Harvard School of Public Health,
Biotechnology and Pharmaceutical IP and Corporate Counsel; Adjunct Lecturer

DOMINIC ADAIR, Bristows,
Partner

ANNA HARRINGTON, Regem Consulting,
Scientific & Regulatory Director

NEIL GRUBERT, Niteo Partners Consulting,
Senior Advisor

RODEINA CHALLAND, Challand Biosimilar Consulting,
General Manager

MARIE MANLEY, Bristows,
Partner, Head of the Regulatory Practice

JACKIE MULRYNE, Arnold & Porter Kaye Scholer,
Counsel

10th Biosimilars & Follow-On Biologics Congregation 2017
9th–10th May 2017, Pestana Chelsea Bridge Hotel, London, UK

Dear Colleagues,

The Biosimilars market is going to heat up considerably over the next three years. Biosimilar versions of a number of major biologic drugs used in the treatment of cancers and rheumatic diseases are expected to complete their development and potentially come on to the market. In order to ensure the sustainability of public healthcare systems, in the context of ageing populations and the growing number of diagnosed chronic diseases, it will be essential to harness the potential of Biosimilars to deliver savings, so that greater numbers of patients can be treated with these medicines. The development of the Biosimilars market is growing exponentially with the industry forecast to be worth $25 billion by 2020.

This conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. This 10th Biosimilars and Follow-on Biologics Congregation 2016 will look at the multiple facets of Biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe, Biosimilar products to the market place. By attending this conference, you will gain a comprehensive outlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

It gives me great pleasure in welcoming all of you to the Virtue Insight's 10th Biosimilars and Follow-on Biologics Congregation 2017.

Regards,

Fen Castro
Head Productions
Virtue Insight

Silver Sponsor

COVANCE
SOLUTIONS MADE REAL®

PLD Sponsor

Woodley BioReg Ltd

Supported By

ConferenceLocate.com

TECHNOLOGY NETWORKS

GoingToMeet
WHERE BUSINESS AND PEOPLE CONVERGE

pharmaphorum
bringing healthcare together

BIOSIMILAR NEWS

Organized By

Virtue Insight

10th Biosimilars & Follow-On Biologics Congregation 2017
9th–10th May 2017, Pestana Chelsea Bridge Hotel, London, UK

SPECIAL REASONS TO ATTEND

- Current market trends and future challenges for Biosimilar success
- Biosimilar development in emerging markets
- Redesigning the Biosimilar business model: What is the optimum business model for Biosimilars?
- Commercial challenges and opportunities - strategies to develop Biosimilars
- Leading Biosimilars companies share their views and strategies on successful market penetration and learn to implement best practices through recent successful strategies and business models – real time case studies
- How do payers see Biosimilars and where is the market going?
- Developing successful business models in Biosimilar product development
- Advances in Biosimilar clinical development and resulting regulatory challenges and opportunities
- Non-Clinical Studies in Biosimilars development
- Biosimilars development and impact on clinical practice
- Capturing the mAb Biosimilar opportunity
- Research-based industry Biosimilar strategies
- Gain in-depth knowledge on role of technology transfer - How does this effect market access?
- Considerations for the analytical similarity assessments when designing a Biosimilar development program
- Determining the right investments & potential returns from Biosimilars
- Understanding the current regulatory approval standards for Biosimilars in Europe, US and ROI including for monoclonal antibodies
- Be part of a major networking opportunity

AN EVENT TO VOW

Get more from the event, enjoy and make the best out of our **dedicated networking drinks time, meet the leading international vendors** showcasing the products of tomorrow in the co-located exhibition. **Expand your knowledge** of the latest business models and strategies in the high-level conference. Whether you are on the branded or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway. Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margins.

WHY EXHIBIT?

Make Sales
Debut new products
Profile your brand
Meet new business partners
Develop key relationships
Educate pharma and biotech companies



WHO WILL YOU MEET

CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins/Biosimilars, Biologics/Biotechnology/ Biogenerics, Legal Affairs, Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affairs, Marketing

10th Biosimilars & Follow-On Biologics Congregation 2017
9th–10th May 2017, Pestana Chelsea Bridge Hotel, London, UK

DAY ONE – 09th May 2017

08:30 – Coffee and registration – An opportunity to meet and network with your conference colleagues.

09:30 – Chairperson opening remarks

DUNCAN EMERTON, Senior Director, Syndicated Insights & Analysis, **FirstWord**

MARKET OVERVIEW & ANALYSIS

09:40 – Payer perspective on biológics and Biosimilars

- NHS payer landscapes post Brexit
- Payers perspectives on Biosimilars and levers for integration into formularies
- Payers perspectives on Parent Innovators - when are payers willing to pay for premium price brands despite Biosimilars?
- Differential Access & Reimbursmemet levers for primary care and hospital settings

OMAR ALI, Visiting Lecturer, **University of Portsmouth and Member of NICE Adoption and Impact Reference Panel**

10:20 – Navigating the mAb biosimilar regulatory maze

- Introduction to Mabs
- What differences might be acceptable
- Aligning of CQAs
- The importance of comparative biological testing
- The role of clinical data in supporting biosimilarity and its limitations

CECIL NICK, Vice President (Technical), **Parexel**

11:00 – Morning Coffee/Tea & Discussion

CHALLENGES & OPPORTUNITIES

11:20 – Keynote Panel Discussion: BREXIT – What impact has it had on the biosimilars industry?

- Global development of biosimilars – vision or reality?
- What will happen to the market size of biosimilars in the emerging market?
- Current - What are the myths and realities about biosimilars in EU & USA?
- How are Big Pharma and Biologics Majors reacting to BREXIT?
- Pros and cons of serving multiple growing markets

Moderator:

DUNCAN EMERTON, Senior Director, Syndicated Insights & Analysis, **FirstWord**

Panellists:

NIRAJ CHHAYA, Senior Risk Management Physician of Biosimilar Compounds, **Boehringer Ingelheim**

SANDY EISEN, Chief Medical Officer, **Frontline Pharma Consulting**

DOMINIC ADAIR, Partner, **Bristows**

CHRISTOPHER STOTHERS, Partner, **Arnold & Porter Kaye Scholer**

SAFETY AND RISK MANAGEMENT PLANNING

12:00 – Planning for Success: A CMC Strategy for Biosimilars

- Importance of CMC
- What is required for successful Biosimilar development
- Building a CMC Biosimilar strategy
- How to de-risk a Biosimilar drug development program

LOUISE ANGELL, Lead Scientist, BioCMC, BioPharmaceutical CMC Solutions – Large Molecules, **Covance**

12:20 – Networking luncheon

BUSINESS MODELS

13:20 – Biosimilar safety strategy: Challenges and Opportunities

OLEKSANDR KARPENKO, Managing Director, **Olexacon**

13:50 – Role of physicians and pharmacists towards strategic business plans

- Can we rely on the regulator – what constitutes 'trusted'
- USA physicians support labels with data to learn about and evaluate biosimilars
- European doctors have insufficient knowledge of biosimilars – they've got company
- Canadian physicians feel strongly about the need to retain sole prescription authority
- 35% of Latin American physicians haven't heard of or could not define biosimilars
- USA hospital pharmacists are more likely to be "Very familiar…" with biosimilars than retail pharmacists (but that's only 44% vs. 23%)
- Lessons to be learnt from pharmacy level substitution in Australia.

STEPHEN MURBY, Alliance for Safe Biologic Medicines, International Advisory Board Member, **International Alliance of Patients' Organizations,** Biosimilars Spokesperson

14:20 – Solution Provider Presentation

For sponsorship opportunities please contact info.uk@virtueinsight.com

---

15:00 – Afternoon Tea/Coffee

15:20 – From biosimilars to biogenerics

- Attitudes and acceptance in clinical practice
- Uptake in clinical practice
- Nor-Switch study and other clinical trials
- Switching and interchangeability

STEINAR MADSEN, Medical Director, **Norwegian Medicines Agency**

16:00 – Presentation TBC

MOURAD REZK, Global Head Medical Affairs (Biosimilars), **Biogen**

16:40 – Panel Discussion: Market access in the EU market and the way forward

- Biosimilars – Market strategies and techniques to overcome the hurdles
- Considerations for successful market of biosimilars
- Market access experiences with initial biosimilars
- Surveying the battlefield: how are the key players lining up?
- Key points in sourcing of comparators
- The way forward

Moderator:

DUNCAN EMERTON, Senior Director, Syndicated Insights & Analysis, **FirstWord**

Panellists:

MAARTEN VAN BAELEN, Market Access Director, **Medicines for Europe**

AMARDEEP UDESHI, Head – Commercial Strategy, **Cipla BioTec (India)**

ALEX KUDRIN, Biopharmaceutical Consultant, **Celltrion**

RODEINA CHALLAND, General Manager, **Challand Biosimilar Consulting**

NEIL GRUBERT, Senior Advisor, **Niteo Partners Consulting**

17:10 – Chairperson's closing remarks and end of conference

17:20 - 18:10 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting

FOR DELEGATE REGISTRATIONS:-

Our potent conference agenda delivering the latest information and the world class leaders as speakers attract delegates to attend from around the world. We aim for our attendees to be equipped with knowledge of latest developments & enable them to network with the industry key personnel.

Delegate Registration - delegate.uk@virtueinsight.com

10th Biosimilars & Follow-On Biologics Congregation 2017
9th–10th May 2017, Pestana Chelsea Bridge Hotel, London, UK

DAY TWO - 10th May 2017

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

09:30 – Chairperson opening remarks

DUNCAN EMERTON, Senior Director, Syndicated Insights & Analysis, **FirstWord**

COMMERCIALISATION & MARKET ACCESS

09:40 – Challenges and Opportunities in Development of Biosimilars vs Biobetters/Biosuperiors

- Explore opportunities for developing biobetters when there is an unmet medical need
- Break down strategies for developing biosimilars versus biobetters
- Consider risks and rewards of biosimilars versus biobetters
- Consider risks and rewards of biobetters versus biosimilars
- Discuss challenges including substitutions, interchangeability and marketing strategy

10:20 – Presentation TBC

ASHUTOSH PATHAK, Senior Director, North America Medical Affairs - Oncology & Biosimilars, **Teva Pharmaceuticals (USA)**

11:00 – Morning Coffee/Tea & Discussion

11:20 – Customized development and production of biosimilars

- Time to market
- High yield expression systems
- Modular flexible production set up
- One stop shop for biosimilars

FEDERICO POLLANO, Director Contract Manufacturing and Business Development, **Polpharma Biologics**

12:00 – Value-Added Medicine - The opportunities and challenges - Similarities to Biosimilars

PETAR BAST, VP Business Intelligence, **Allergan**

12:30 – Networking luncheon

13:30 – Growing role of patients groups in risk benefit assessment, technology appraisal and R&D sponsorship

ANNA HARRINGTON, Scientific & Regulatory Director, **Regem Consulting**

14:00 – Obtaining patent protection while operating in an "anti-patent" climate

- Overview of recent cases affecting the biotechnology industry
- Impact on biosimilar development
- Strategies for obtaining adequate patent protection

JOANNA BROUGHER, Biotechnology and Pharmaceutical IP and Corporate Counsel; Adjunct Lecturer, **Harvard School of Public Health**

14:30 – Solution Provider Presentation

For sponsorship opportunities please contact info.uk@virtueinsight.com

---

15:10 – Afternoon Tea/Coffee

15:30 – Biosimilars – 10 years' experience – what have we learnt and what challenges are there going forward from a medical affairs perspective

MATTHEW TURNER, Global Medical Director Biosimilars, **Merck KgA**

REGULATION OVERVIEW & UPDATE

16:10 – Panel Discussion: The developing regulatory framework in advanced and developing markets – for Today & Tomorrow

- The latest in regulatory thinking - Update and current trends for EU and US biosimilar approvals, new and future guidelines. What has changed? – Get yourself updated.
- What is the best way for industry to present data to the regulatory authorities?
- Regulatory changes necessary to maximize biosimilars potential
- How similar is similar? What is likely not to be accepted by the regulator?
- What types of additional risk minimisation measures may be necessary?
- IP and regulatory rights

Moderator:

DUNCAN EMERTON, Senior Director, Syndicated Insights & Analysis, **FirstWord**

Panellists:

MOURAD REZK, Global Head Medical Affairs (Biosimilars), **Biogen**

ASH RAMZAN, Principal Consultant, **Woodley BioReg**

MOHAMED OUBIHI, Managing Director, **Yakumed**

MARIE MANLEY, Partner, Head of the Regulatory Practice, **Bristows**

JACKIE MULRYNE, Counsel, **Arnold & Porter Kaye Scholer**

16:50 – Chairperson's closing remarks and end of conference

DUNCAN EMERTON, Senior Director, Syndicated Insights & Analysis, **FirstWord**

17:00 – End of the 10th Biosimilars Congregation 2017

FOR SPONSORSHIP OPPORTUNITIES:-

Sponsorship or exhibition is the best way to speed network with decision makers. The world leader speakers in our conferences attract niche delegates from all over the world. This would be a wonderful opportunity to reach the right audience and save money and time on all your other advertising gimmicks. To give you an advertising edge we constantly update the industry pioneers via emails/news letter about the event and advertise the event via different forms of media.

Sponsorship Enquires - sponsor.uk@virtueinsight.com

10th Biosimilars & Follow-On Biologics Congregation 2017

FLOOR PLAN - Book your stalls now before they run out !!!



1	5	9
2	6	10
3	7	
4	8	

Note :- The floorplan is subject to change at the discretion of the organisers.

PAST ATTENDEE LIST

3P Biopharmaceuticals S.L - Scientific Director
Abbott - Market Development & Reimbursement Manager
Abbvie - Strategy Manager
Abbvie - Head of Government Affairs
Abbvie - Biotherapeutic Lead
Abbvie - Senior Director
AbbVie B.V. - Governmental Affairs Director
AbbVie Netherlands - Medical Lead Biotherapuetics
Abdi Ibrahim Ilac San - R&D and Business Development VP
Abdi Ibrahim Ilac San - Business Development Director
Abdi Ibrahm - Business Development Supervisor
Accelera srl - Senior Account Manager Business Development
Actavis Biologics - Purification Development Team Leader
Albany Molecular Research - Regional Sales Director
Amgen - Regulatory Affairs Manager - EU Policy
Amgen - Director, Biosimilars Operations
Antitope - Director, Scientific Affairs & Technology Evaluation
Antitope - Cell Line Development Group Leader
Antitope - Business Development Associate
Apitope International - Business Development Manager
appliedstrategic - CEO Founder
appliedstrategic - Applied strategic Analyst
Arnold & Porter - Partner
Atheln, Inc - Managing Director – Commercial Practice
Baxalta Innovations Gmbh - Manager, Downstream Process Science
Baxter Healthcare - Medical Director
Baxter Innovations - Associate Medical Director
Bayer Pharma - Head Clinical Pharmacokinetics
BioAgilytix Labs
Bioceros Holding BV - Managing Director & COO
Bioceros Holding BV - Director Cell Line development
Bioceros Holding BV - Business Developer
BioFrontline
BioKinetic Europe - Business Development & Marketing Associate
BioKinetic Europe - Senior Project Manager
Biologicals Advice - Managing Director
BioOutsource - CEO
BioOutsource - Director of Sales & Marketing
BioOutsource - Head of Biosimilars
BioProcess Technology Consultants - President and Principal Consultant
BioProcess Technology Consultants - Vice President and Senior Consultant
Biosimilars News
Biotechpharma UAB - CEO
Bioton S.A.
BioXpress Therapeutics - Head Project Management
Bird & Bird - Partner
Boehringer Ingelheim - Senior Patent Counsel
Boehringer Ingelheim - Sr. Clinical Program Leader Biosimilars
Boehringer Ingelheim - Corporate Affairs Manager
Boehringer Ingelheim - Biosimilars Study Manager
Boehringer Ingelheim Pharmaceuticals - Project Compliance Manager
BofA Merrill Lynch - Associate
Bristows - Commercial and IP Associate - Life Sciences Sector
Bristows - Partner & Head of the Regulatory Practice
Bristows - Partner
Broughton Laboratories - Operations Director
Business Vibes
Business Wire
Cambridge Healthcare & Biotech - Director
Catalent Pharma Solutions - Business Development Account Director
Celltrion - VP and Head of Global Development
Cinfa Biotech - Director Clinical Operations
Clinigen CTS - Global Head of Business Development and Strategic Services
Clinigen CTS - EU Director of Business Development
CMC Biologics A/S - Director, Corporate Business Development
CMC Biologics A/S - Director, Corporate Finance & Business Analysis
Conference Locate
Covance - Director: global regulatory strategy
Covance Laboratories - Senior Director, Programme Management
Covance Laboratories - Principal Scientist
Covance Laboratories - Associate Director Biosafety
Covance Laboratories - Lead Scientist
Covance Laboratories - Lead Scientist at Global CRO (GCP/GLP/GMP)
Covance Market Access Services - Senior Consultant
Crystal Clear Conferences - Director
DASGIP Information and Process Technology - Bioprocess Sales Specialist
Datamonitor Healthcare Consulting - Principal Consultant
Denka Seiken - Manager
Domainex - Chiarman
Dong A Pharmaceutical - Global Stratergy & Corprate Development Vice President
DRG - Senior Director, Biosimilars Research
DRG - Principal Analyst, Biosimilars Research
DRG - Research Associate, Biosimilars Research
DSM Biologics - Director Business Development
Dutch Health Care Inspectorate - Coordinating/Specialized Senior Inspector
Eli Lilly - Senior Medical Fellow, Clinical Pharmacology
Eli Lilly - Policy and Communications Manager, ACE
Eli Lilly - Director, BioPharmaceuticals
Ellis Pharma - Business Development Manager
ERA Consulting - Group Director of Regulatory Affairs
Euro Diagnostica - UK Marketing Director
Eurofins Lancaster Laboratories - Section Manager of Biopharm Dept
Eurofins Lancaster Laboratories - Team Leader of Biopharm Dept
Eurofins Lancaster Laboratories - Scientist, Biopharm Dept
Eurofins Lancaster Labs - Managing Director
Eurofins| Lancaster Laboratories - Business Development Executive
Evidera - Senior Principal, Global Payer Strategy Consulting
FirstWord - Executive Editor
FirstWord - Senior Director, Syndicated Insights & Analysis
Fisher Clinical Services - Business Development Manager
Fisher Clinical Services - Manager, Business Development
Fisher Clinical Services - Ass. Dir. Comparator Sourcing
Fisher Clinical Services - Head Commercial Operations
Flanders Bio
Formycon AG - CEO
Fresenius Kabi Deutschland - Director Medical-Scientific Management
Frontline Pharma Consulting - Chief Medical Officer
Frost & Sullivan - Program Manager, Life Sciences, Healthcare
Frost & Sullivan - Global Program Manager, Life Sciences
Genovis - Director Sales & Market development
Genovis - Director of Customer Relations
GEROPHARM - VP, Strategic Development
GEROPHARM - Head, Clinical affairs
Glenmark Generics - Business consultant
Going to Meet
Good Clinical Practice Alliance – Europe (GCPA) - Executive Director
Hameln RDS - Vice President / Sales and Marketing
Healthcare at Home - Commercial Director – Rare and Orphan Diseases
Herbert Smith Freehills LLP - Lawyer
Hisut - Consultant
Hospira - Biosimilars and Proprietary Marketing Director - EMEA
Hospira - Vice President - Biologics
Hospira UK - Head of Oncology, EMEA
Hospira UK - Director of Auto-Immune, EMEA
Hospira UK - Product Manager, EMEA
Huntingdon Life Sciences - Chief Scientific Officer - Biologics
HYPERMARCAS
ICON Clinical Research - Director, Project Management
IDDI - Business Development Assistant
IDT Biologika GmbH - Senior Key Account Manager
IDT Biologika GmbH - Manager Sales
IMS Health - Principal, Global Generics, Thought Leadership
Infinata, Inc - Journalist
Innovaro
INSERM - Director of Research, Laboratory of Biotechnology and Applied Pharmacology
InSight Biopharmaceuticals - Executive VP
Interpharm Consultancy - Senior Consultant
IPPro Lifesciences - Account manager
ISU Abxis - Senior Manager
Janssen Biologics B.V. - Sr. Clinical Project Specialist, Medical Affairs Europe
JHL Biotech - Sr. Director
KEYPHARMA PLG - Associate Director
LEO Pharma - Thrombosis Commercial Account Manager UK/IE
Lupin Limited (Biotech Division) - Senior Manager, BD and Global Licensing
Luther Pendragon - Managing Director

PAST ATTENDEE LIST

Makovsky - Senior Vice President
Markets&Markets
Medac - PM Portfolio Development Autoimmune
medac GmbH - Global Product Manager
Menarini Biotech Srl - CMO Business Development
Merck - Head of Safety, Biosimilars
Merck Millipore - Director WorldWide Biosimilars Market, Process Solutions
Merck Millipore - Bioscience - Sales Manager | Bulk and Custom Solutions Europe
Merck Serono - VP - Business Development and Alliance Management, Biosimilars
Merck Serono - Project Coordinator, Biosimilars
Merck Serono - Global Brand Manager & Global Biosimilars Business Intelligence
Merck Serono - Director - Alliance Management (Biosimilars)
MHRA - Non-Clinical Assessor
MHRA - Biologicals and Biotech Unit
MHRA - Clinical Assessor
MHRA - Biologicals Quality Assessor
MHRA - Medical Assessor in Licensing of Biological Products
Minapharm Pharmaceuticals - Senior Manager Biopharmaceutical Projects
Minapharm Pharmaceuticals - R&D Manager Process Development
Minapharm Pharmaceuticals - Associate R&D Manager Technical Operations
MSD - Head Of Strategic Pricing
MSD Ireland Carlow - Director, Engineering
Mundipharma - Sales & Marketing Director
Mundipharma - Team Leader Oncology
Mundipharma Comm - Medical Officer
Mundipharma International - Head of Respiratory & Inflammation
Mundipharma Intl - Commercial Lead Biosimilars
Mylan - Sales Director
Mylan - Hospital Account Manager - Team Leader
Mylan - Hospital Sales Manager
Mylan - Product Marketing Manager
Mylan EPD - Commercial Portfolio Director
Mylan Healthcare GmbH - Senior Manager Regulatory Affairs
Mylan Healthcare GmbH - Director Regulatory Affairs
Mylan Hospital & Retail - Sales Manager
Myoderm - Business Development Specialist
Napp Pharmaceuticals - Medical Science Liaison
NDA - Biologics and Advanced Therapies Expert
NDA Regulatory - Advisory Board Member
Norweigen Medicines Agency - Medical Director, Department of Drug Information
Norweigen Medicines Agency - Medical Director
Novartis Pharma AG - Global Program Regulatory Director
Oasthouse Consulting - Principal Consultant
OCT - Head, Clinical Operations
Olam International - Country Manager Germany, Austria and Switzerland
Omnicare Pharma GmbH - Head of Business Development
Omnicare Pharma GmbH - Business Analyst
Omnicare Pharma GmbH - Business Development Manager
ORION Clinical Services - Director of Project Development and Scientific Affairs
PAREXEL - Vice President, Biotechnology,
PAREXEL International - Director, Early Phase Business Development
Patheon - Business Development Executive
PerkinElmer - European Business Development, Life Sciences & Technology Division
Petra Drug Store - Regulatory Affairs & Q.A. Manager
Pfizer - Director Biosimilars Strategy
Pfizer - Senior Manager, International Policy
Pfizer - Medical Lead Rheumatology
Pfizer - Oncology Portfolio Global Medical Lead-Biosimilars
Pfizer - Senior Scientific Adviser
Pfizer - UK Tender Manager
Pfizer - Portfolio Team Leader
Pfizer-Hospira - Director & Infliximab Global Team Lead
Pharma Mirror - Advisory Editor
Pharma Mirror - Super contributor
Pharma Voice
PharmaPhorum - Customer Service Executive
Pharmaphorum - Managing Editor, Feature Media
Pharmcast
Pharminvent - CEO
PharmSource Information Services - Director Market Intelligence
PIONEERA HealthCare Group - Chairman & CEO
PPD - Associate Director Regulatory Affairs
PPD - Senior Manager Regulatory Affairs
PPD - Senior Specialist Regulatory Affairs
PPI - Director
Prediction BioSciences - CEO
Protagen Protein Services - Chief Business Officer
Protagen Protein Services - CEO
Protagen Protein Services GmbH - Director - Business Development
QPS Holdings LLC - VP Bioanalysis & Technology R&D
Quintiles - Business Director Drug Development Asia
Quintiles - Head Site Training & Biosimilar Site Strategy
Quintiles - Vice President
R2S (CRO) - General Manager
Regem Consulting - Scientific & Regulatory Director
Richter Helm Biotec - Managing Director
Roche AB - Business and Innovation Manager
Roche Products - Medical Manager
Roche Products - National Programmes Manager
Roche Products - Senior Brand Manager
Roche Products Ireland - Pipeline & Operational Pricing Manager
Rpharm - Chief Medical Officer
Rpharm - CEO and CSO
Rpharm - VP of Global Partnering
RSA - Consultant
SACHEM, Inc - Global Marketing Manager-Biotechnology
SAI MedPartners - Project Manager
SAI MedPartners LLC - Director
Sandoz - Head of Biopharmaceuticals
Sanofi - BD & New product Planning Exe
Sanofi Aventis - Market Access Director
Sanofi Aventis - Business Strategy & Market Access Director
Sanofi Aventis - Health Economist Manager
SCM Pharma - Quality Director
Securing Industry
Serbia-Alims - Expert of medicines and medical devices agency
SGS Life Science - BDM, Biochemical Services – Laboratory Services
SGS Life Science - Global Director, BioPharma Services Development
SGS Life Science - Sales Manager, Biochemical Services - Laboratory Services
SGS M-Scan - Global Director
Sidley Austin - Partner
Sothema Laboratories - Marketing & B. Development Director
Sothema Laboratories - Quality Director
Sothema Laboratories - Regulatory affairs Director
Spectrum Regulatory Solutions - Science Director
Stragen Pharma SA - Biotechnology Product Manager
Takeda Pharmaceuticals - Medical Director
Teva Pharmaceutical - Senior Director and Global Head of Bioassays
Teva Pharmaceuticals - Director, Strategy & Global Business Development
Teva Pharmaceuticals - Director
The Wall Street Journal - Reporter
Thompson Media Group - Staff Writer
TikhePharma - Founder & CEO
Triskel Integrated Services - CEO
TWC Pharma Consulting - CEO
UBC - Senior Project Director
UBC - Senior Project Mnat Manager
UCL Hospitals NHS Trust, University of London - Associate Professor in Clinical Pharmacy Practice (Honorary)
Vela Labs GmbH - Head Laboratory
Vifor Pharma - Professor
Virdisgroup - Head Consultant
Voisin Consulting Life Sciences - Director
West Pharmaceutical Services - Director, Business Development
West Pharmaceutical Services - Manager Marketing Projects Europe
Wockhardt UK - Managing Director
Wockhardt UK - Associate Director Regulatory & Drug Safety
Woodley BioReg - Principal Consultant
Worldwide Clinical Trials - Vice President Business Development International
Worldwide Clinical Trials - Director, Business Development
Yakumed - Managing Director

10th Biosimilars & Follow-On Biologics Congregation 2017

9th–10th May 2017

Registration Form

For Multiple Bookings - Photocopy this form and send it to delegate.uk@virtueinsight.com; Tel:+44 2036120886

Delegate Details:

Title Mr ☐ Mrs ☐ Ms ☐ Dr ☐

First Name

Surname

Company

Position

Address

Postcode

Telephone

Fax

Email

How to Pay
(Choose one of the following payment options)

RESERVATION PRICING:

Early Bird - £950 + VAT per delegate (Valid From 11th February 2017 - 24th March 2017) ☐

Standard Rate - £1150 + VAT per delegate (Valid From 25th March 2017) ☐

PAYMENT:

Please send me a VAT invoice ☐

I enclose a cheque for £

Please charge my card £

Card Number

Security No

Expiry Date /

Cardholder's Name

Cardholder's Registered Address

Signature

Our purchase order no.is

Payable to **Virtue Insight Events Ltd**

Card type: Visa ☐ Mastercard ☐ Maestro ☐

(Please note that we do not take Amex card payments)

FOR BANK TRANSFER:

Account Name - Virtue Insight Events Ltd **Account Number** - 53278603

Bank Name - Barclays Bank PLC **Sort Code** - 20-84-20

SWIFT Code: BARCGB22 **IBAN Code:** GB36BARC20842053278603

ROUTING Code: 026002574

Special Offer:

3 for 2 Offer

*Only few more seats left

TERMS AND CONDITIONS:

Payment terms: Virtue Insight requires the full amount to be paid before the conference. We may refuse entry to delegates who have not paid their invoice in full.

Cancellations: Delegates and vendor are subject to the following charges and refunds upon withdrawal or cancellation.Between 2-3 month's prior 75% cancellation fee/ 25% refund.Less than 2 months prior to the event Full cancellation fee / No refund.

Substitutions/Name Change: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. This can be done at not extra cost.

Presentation: If you cannot attend the conference, you can still purchase the presentations for £ 400 + VAT

Indemnity: Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will refund your registration fee and we will try to reschedule the event.

Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel accommodation.

How we will contact you: Virtue Insight's preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.

UPCOMING CONFERENCES:

- **10th Annual Cloud Computing & Big Data Analytics 2017 - 22nd March 2017, Bangalore, India**
- **10th Biosimilars Congregation 2017 - 09th - 10th May 2017, London, UK**
- **8th Annual Clinical Trials Summit 2017 - 24th May 2017, Mumbai, India**
- **4th IoT Summit 2017 - 27th July 2017, Bangalore, India**
- **11th Biosimilars Congregation 2017 - 07th September 2017, Mumbai, India**
- **6th Annual Pharma AntiCounterfeiting & Serialisation 2017 - 13th - 14th September 2017, London, UK**
- **13th Pharmacovigilance 2017 - 27th - 28th September 2017, Chicago, USA**
- **14th Pharmacovigilance 2017 - 09th November 2017, Mumbai, India**
- **3rd Annual Pharma Pricing, Reimbursement & Market Access 2017 - 15th - 16th November 2017, London, UK**

For more info on these summits - Kindly contact us at -

Phone - (India) - + 91 44 64536444
Phone - (UK) - + 44 - 2036120886

Email - (India) - info@virtueinsight.com
Email - (UK) - info.uk@virtueinsight.com

Virtue Insight:-

Virtue Insight equips business professionals around the world with the latest indepth industry knowledge and provides networking opportunities in the telecom, infrastructure and pharmaceutical industry. Our aim is to provide a platform to share knowledge and insights and provide our event attendees to network effectively and deliver maximum ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Our motto is to offer our customers the expertise and connections for a profitable business. Our events encompass an optimum chance to gain maximum value in terms of networking and an opportunity to sponsor and exhibit to attract new business alliances.